Board Accountability at Insurers: IRDAI's 2024 Master Circular on Corporate Governance

On 22 May 2024, the Insurance Regulatory and Development Authority of India (IRDAI) issued the Master Circular on Corporate Governance for Insurers, 2024 (Ref IRDAI/F&I/CIR/MISC/82/5/2024), the operational rulebook that puts flesh on the bones of the IRDAI (Corporate Governance for Insurers) Regulations, 2024, notified two months earlier on 21 March 2024. Together, these two instruments reset how the board of every Indian insurer must be composed, how many committees it must run, and who inside the company is personally accountable for protecting a policyholder's claim.

This matters to ordinary buyers because governance is not an abstraction. When a claim is rejected, a bonus is under-declared, or an investment portfolio wobbles, the trail almost always leads back to a board committee that either did its job or did not. This deep dive explains the 2024 circular clause by clause, works through the compliance arithmetic, and flags the governance traps that quietly decide whether your money is safe.

The Rule / Product

The 2024 Master Circular derives its authority from three statutory pegs: Section 34 of the Insurance Act, 1938, Section 14 of the IRDA Act, 1999, and Regulation 12 of the Corporate Governance for Insurers Regulations, 2024. It became effective on issuance (22 May 2024), but IRDAI gave insurers until 30 June 2024 to align their existing structures. It applies to every insurer except a foreign company writing reinsurance through a branch established in India.

At the centre of the circular sits the board of directors. Clause 2.1 requires an "optimum composition" of independent and non-executive directors, subject to a hard floor of a minimum of three independent directors. The board must also carry at least one woman director, a requirement the circular imports directly from Section 149 of the Companies Act, 2013. Each independent director must satisfy the full independence tests in Section 149 and hold a written appointment letter setting out duties and sitting fees.

The board's quorum is fixed by a simple formula in Clause 2.1(b): one-third of the total strength of the board, or three directors, whichever is higher. So a small board cannot transact governance business with two people in the room, however convenient that might be.

On the chair, the circular sets a clear expectation of separation of powers. Clause 2.1(f) states that, to promote checks and balances, it is good practice for the chair of the board to be a non-executive member and not to serve as chair of any board committee. Any proposal to appoint a chairperson needs prior approval of the Competent Authority via Forms A, B and C in Annexure 1, and a sitting chairperson as on 22 May 2024 may continue only up to 31 March 2026 or the end of the current tenure, whichever is earlier.

The heart of the delegation architecture is a set of six mandatory committees the board must constitute. The table below lists them alongside the meeting cadence set by Clause 4.9.

Two more committees sit outside the mandatory six: the With-Profits Committee, required only for life insurers (Clause 4.7), and the Ethics Committee, which Clause 4.8 leaves optional. The Audit Committee carries the tightest rules of all: under Section 177 of the Companies Act, 2013, it must have a minimum of three directors, a majority of them independent, and the chair of the board cannot be a member of it.

Below the board, the circular defines the Key Management Persons (KMPs) who run the company day to day. Clause 5.2 makes the CEO, Managing Director or Whole-Time Director responsible for conducting the insurer's affairs consistently with board policy and never detrimentally to policyholders; every such appointment needs prior IRDAI approval, with the proposal submitted at least one month before the incumbent's tenure ends. Clause 6 then creates an independent compliance backbone: a Chief Compliance Officer appointed for a minimum fixed tenure of three years, reporting directly to the board or a board committee, with no reporting relationship to any business vertical.

Why It Matters

Insurance is a fiduciary business. The circular's own Clause 1 frames it plainly: insurers accept "public liabilities for fulfilment of certain contracts", so the relationship carries "enhanced responsibility to protect the interests of all stakeholders". Every governance rule in the 2024 document, from the three-independent-director floor to the CCO's three-year tenure, exists to keep that fiduciary promise enforceable.

Consider the Policyholder Protection, Grievance Redressal and Claims Monitoring Committee, made mandatory by Clause 4.4. Its very existence means that claim-handling and grievance data must be reviewed at board level at least four times a year. If you have ever wondered who inside an insurer answers for a wrongly repudiated claim, this is the committee that must monitor it, using the same underwriting and claims data an actuary relies on to price the product in the first place.

The CCO independence rule in Clause 6(e) matters for the same reason. By barring the Chief Compliance Officer from any reporting line into sales or underwriting, the circular tries to ensure that the person flagging an Anti-Money-Laundering breach or a mis-selling pattern cannot be silenced by the very business unit under scrutiny. That is reinforced by the Clause 11 whistle-blower policy, which since 30 June 2024 every insurer must maintain so that employees can report governance weaknesses in confidence directly to the board chair or the statutory auditor.

Governance also polices conflicts of interest. Section 48A of the Insurance Act, 1938, read with Clause 2.2 of the circular, governs "common directors" who sit on both an insurer's board and that of an agent or intermediary. Such a director must recuse from any discussion or vote where a conflict arises, a rule that protects the sum assured promised to you from being quietly compromised by cross-holdings you never see.

Worked Numbers

Corporate governance rarely comes with a rupee figure, but the 2024 circular is unusually quantitative. The arithmetic below shows how a compliance officer would actually apply it to a mid-sized insurer with a ten-member board.

Quorum. Clause 2.1(b) sets quorum at one-third of total strength or three directors, whichever is higher. One-third of ten is 3.33, which rounds up to 4 whole directors; the higher of 4 and 3 is 4. So this board needs four directors present to transact business. The table shows how the number moves with board size.

Composition floor. Of those ten seats, at least three must be independent directors (Clause 2.1(a)) and at least one must be a woman director (Clause 2.1(h), tracking Section 149 of the Companies Act, 2013). A board that has only two independent directors is non-compliant the moment the circular's 30 June 2024 deadline passes, regardless of how capable those two are.

Audit Committee maths. Under Section 177 of the Companies Act, 2013, the Audit Committee needs a minimum of three directors with a majority independent. On a three-member committee, "majority independent" means at least two of the three must be independent directors, and the board chair cannot occupy any of the three seats.

Meeting cadence. Clause 4.9(a) requires each mandatory committee (except the Nomination and Remuneration, CSR and With-Profits Committees) to meet at least four times a year, with no more than four months between two successive meetings. A committee that met in January and then not again until June, a five-month gap, would breach the circular even if it hit four meetings across the calendar year. The Investment Committee faces a stricter beat under Clause 4.2(h): at least once every quarter, reporting portfolio safety and soundness to the board each time.

The point of this arithmetic is that governance compliance is auditable to the director and to the month. A board cannot claim "substantial compliance" when the circular counts three independent directors, four meetings, and four-month gaps with no rounding in the insurer's favour.

Pitfalls

The governance traps below are the ones that most often surface in IRDAI inspection findings, each tied to a specific clause.

Trap 1 - the chair who wears too many hats. Clause 2.1(f) discourages the board chair from chairing any committee, and Clause 4.1(a) flatly bars the chair from even being a member of the Audit Committee. A common structural error is an executive chair who also chairs the Audit or Risk committee, collapsing the very checks and balances the circular is built to create.

Trap 2 - the CEO inside the audit tent. Clause 4.1(c) limits the CEO's association with the Audit Committee to occasions where the committee needs specific information on audit findings. Treating the CEO as a standing participant undermines the committee's independence and is a recurring inspection observation.

Trap 3 - a compliance officer reporting into sales. Clause 6(e) prohibits any reporting relationship between the CCO and business verticals. An insurer that parks compliance under the Chief Business Officer to "save headcount" has breached the circular and hollowed out its own AML and mis-selling defences.

Trap 4 - the conflicted common director who does not recuse. Under Section 48A of the Insurance Act, 1938 and Clause 2.2(a)(vi), a director common to an insurer and an intermediary must recuse from any conflicted matter. Failure to record that recusal in the minutes is a governance breach even if no harm results.

Trap 5 - missing the four-month clock. Because Clause 4.9(a) caps the gap between committee meetings at four months, insurers that batch two meetings close together and then leave a long silence can be non-compliant despite hitting the annual count of four.

These governance failures are not academic; they feed straight into product-level harm. Weak oversight of the claims committee is exactly how policyholders end up ambushed by a sub-limit, a co-payment clause, or a pre-existing disease waiting period they never understood. When you compare cover on our term insurance premium calculator or weigh a market-linked plan on the ULIP vs mutual fund calculator, the strength of the insurer's board sits invisibly behind every number. A quick check of the insurer's governance disclosures is as worthwhile as running the health insurance premium calculator before you buy.

FAQ

What exactly changed on 22 May 2024?

IRDAI issued the Master Circular on Corporate Governance for Insurers, 2024 (Ref IRDAI/F&I/CIR/MISC/82/5/2024), the operational companion to the Corporate Governance Regulations notified on 21 March 2024. Insurers had until 30 June 2024 to comply, and the circular consolidated board, committee and KMP governance into a single instrument.

How many independent directors must an insurer's board have?

At least three, under Clause 2.1(a) of the 2024 circular. The board must additionally include at least one woman director, tracking Section 149 of the Companies Act, 2013, and each independent director must meet the full independence tests in that section.

Which board committees are mandatory?

Six: the Audit, Investment, Risk Management, Policyholder Protection Grievance Redressal and Claims Monitoring, Nomination and Remuneration, and Corporate Social Responsibility committees. Life insurers must also run a With-Profits Committee under Clause 4.7, while the Ethics Committee under Clause 4.8 is optional.

How often must these committees meet?

At least four times a year, with no more than four months between successive meetings, under Clause 4.9(a). The Nomination and Remuneration, CSR and With-Profits committees are exceptions, and the Investment Committee must meet at least once a quarter under Clause 4.2(h).

Can the same person be board chair and CEO?

The circular strongly discourages it. Clause 2.1(f) treats a non-executive chair as good practice, and Clause 4.1(a) bars the chair from being a member of the Audit Committee, so combining the roles undercuts the checks the circular is designed to build.

What protection does the Chief Compliance Officer arrangement give policyholders?

Under Clause 6, the CCO holds a minimum fixed tenure of three years, reports directly to the board or a board committee, and has no reporting line into any business vertical. This independence is meant to ensure that AML failures and mis-selling patterns can be escalated without commercial interference.

Does the circular apply to every insurer in India?

Almost. It applies to all insurers except a foreign company writing reinsurance through a branch established in India, and it took effect on issuance on 22 May 2024 with a compliance deadline of 30 June 2024.